
Anixa Biosciences Inc — Investor Relations & Filings
Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-03-11 | English | |
| 10-Q | 2026-03-09 | English | |
| 8-K Filing | 2026-02-09 | English | |
| 4 Filing | 2026-01-29 | English | |
| DEF 14A Filing | 2026-01-28 | English | |
| 10-K Filing | 2026-01-12 | English |
Browse filings by year
32 years- 2026 13 filings
- 2025 32 filings
- 2024 30 filings
- 2023 20 filings
- 2022 36 filings
- 2021 48 filings
- 2020 36 filings
- 2019 39 filings
- 2018 41 filings
- 2017 66 filings
- 2016 46 filings
- 2015 126 filings
- 2014 79 filings
- 2013 50 filings
- 2012 43 filings
- 2011 25 filings
- 2010 32 filings
- 2009 16 filings
- 2008 15 filings
- 2007 21 filings
- 2006 19 filings
- 2005 23 filings
- 2004 27 filings
- 2003 14 filings
- 2002 7 filings
- 2001 9 filings
- 2000 6 filings
- 1999 8 filings
- 1998 5 filings
- 1997 7 filings
- 1996 12 filings
- 1995 7 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 46076185 | 8-K | 2026-03-11 | English | ||
| 46076247 | 10-Q | 2026-03-09 | English | ||
| 18168263 | 8-K Filing | 2026-02-09 | English | ||
| 18168267 | 4 Filing | 2026-01-29 | English | ||
| 18168260 | DEF 14A Filing | 2026-01-28 | English | ||
| 18168268 | 10-K Filing | 2026-01-12 | English | ||
| 18168261 | S-8 Filing | 2026-01-12 | English | ||
| 18168271 | SCHEDULE 13D/A Filing | 2026-01-06 | English | ||
| 18168270 | 4 Filing | 2026-01-06 | English | ||
| 18168266 | 4 Filing | 2026-01-06 | English | ||
| 18168264 | 4 Filing | 2026-01-06 | English | ||
| 18168262 | 4 Filing | 2026-01-06 | English | ||
| 18168258 | 4 Filing | 2026-01-06 | English | ||
|
2025
2 filings
| |||||
| 18168265 | 4 Filing | 2025-12-16 | English | ||
| 18168269 | 8-K Filing | 2025-12-12 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
BenevolentAI
Applies artificial intelligence to accelerate drug discover…
|
BAI | LU | Professional, scientific and te… |
|
Berry Genomics Co.,Ltd
Provides clinical genomics and genetic testing for prenatal…
|
000710 | CN | Professional, scientific and te… |
|
BetterLife Pharma
Developing non-hallucinogenic neuroplastogens for severe ne…
|
BETR | CA | Professional, scientific and te… |
|
BGI Genomics Co., Ltd.
Provides integrated solutions for precision medicine via ge…
|
300676 | CN | Professional, scientific and te… |
|
bioAffinity Technologies, Inc.
Develops noninvasive diagnostics and targeted therapeutics …
|
BIAF | US | Professional, scientific and te… |
|
BioArctic
Biopharmaceutical firm developing antibody therapies for ne…
|
BIOA | SE | Professional, scientific and te… |
|
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Develops antibody therapeutics using proprietary RenMice ge…
|
688796 | CN | Professional, scientific and te… |
|
BIO-GENE TECHNOLOGY LTD
Develops novel insecticides from natural chemistry to comba…
|
BGT | AU | Professional, scientific and te… |
|
BioInfra Co.,Ltd.
Develops multi-biomarker blood tests for early cancer scree…
|
199730 | KR | Professional, scientific and te… |
|
BioInfra Life Science Inc.
Develops multi-biomarker blood tests for early cancer scree…
|
266470 | KR | Professional, scientific and te… |
Anixa Biosciences Inc via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34117/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34117 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34117 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34117 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34117}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Anixa Biosciences Inc (id: 34117)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.